Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients - Biognosys

Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Seminar Recordings

This webinar reveals how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities. Jean-Marie Michot, a medical oncologist at Gustave Roussy Institute and Vito Dozio, Scientific Project Manager at Biognosys, share a study that illustrates the promise of proteomics in understanding responses to new therapies such as anti-IL-6-based treatment and the impact of comorbidities on clinical outcomes.

GenomeWebinar April 27, 2021
Oncology in the Time of COVID-19: Quantitative Proteomic Analysis of Anti-IL6 Treated Patients

Back to Resources overview

Contact

    By submitting this form, you confirm that you consent to Biognosys processing of your personal data for the purposes and in the manner as described in our Privacy Notice.

    Close banner

    New: Spectronaut® 19

    Unlock Your Data's True Story

    New: Spectronaut® 19

    Unlock Your Data's True Story

    Learn More